The literature includes several studies that have shown that null polymorphisms in GSTM1 could increase the risk of cancer of the head and neck, as well as oral cancer [45,47], breast cancer [50], and lung cancer [51,52]. This evidence concerns the gene GSTM1 and lung carcinoma.